Printer Friendly

WRONGFUL DISCHARGE SUIT FILED AGAINST MUTUAL PHARMACEUTICAL ON BEHALF OF FORMER EMPLOYEE WHO WAS ABOUT TO NOTIFY FDA AND FBI OF ILLEGAL PRACTICES

 PHILADELPHIA, June 15 /PRNewswire/ -- Today, a wrongful discharge suit was filed in the U.S. District Court for the Eastern District of Pennsylvania by the Philadelphia law firm of Lovitz & Gold, P.C., on behalf of Nagesh Shirsat, former production manager of Mutual Pharmaceutical Company, Inc. of Philadelphia.
 Hyman Lovitz, Shirsat's attorney, alleges that Shirsat was terminated from his job because he refused to participate in the drug company's several illegal activities and threatened to notify both the Federal Food and Drug Administration and the Federal Bureau of Investigations about them.
 "Shirsat protested and refused to participate," explained Lovitz, "in the company's inappropriate storage of chemicals, its failure to maintain written records, its interchanging of labels on various drug lot numbers, and its falsification of records and re-working of drug lots without the approval of the FDA. He complained of these activities and said he would not be a part of them many times.
 "Finally, on April 16, 1992," Lovitz continued, "Shirsat informed Mutual that he intended to report the above illegal activities to federal law enforcement agencies. In alleged retaliation, the drug company terminated his employment on April 30, 1992.
 "Mutual's actions," Lovitz concluded, "are in violation of public policy which precludes an employer from terminating employment in retaliation for an employee's refusal to violate the Federal Food, Drug and Cosmetic Act; and other federal and state laws that pertain; and for stating his intention to report illegal activities to the appropriate law enforcement agencies."
 The termination of Shirsat's employment, Lovitz further said, constitutes a wrongful discharge, in that Pennsylvania law precludes the termination of employment in retaliation against an employee refusing to violate federal law and perform an unlawful act.
 Shirsat is seeking reinstatement to his former position of employment, together with compensatory and punitive damages.
 /delval/
 -0- 6/15/93
 /CONTACT: Hyman Lovitz of Lovitz & Gold, P.C., 215-569-1999/


CO: Mutual Pharmaceutical Company, Inc.; Lovitz & Gold, P.C. ST: Pennsylvania IN: MTC SU:

CC-MP -- PH005 -- 2049 06/15/93 10:59 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 15, 1993
Words:335
Previous Article:HAMPTON RESOURCES EXTENDS ODD LOT TENDER OFFER
Next Article:EGGHEAD SOFTWARE FEATURES NEWEST BUSINESS SOFTWARE AT FREE, PORTLAND-AREA SEMINAR
Topics:


Related Articles
U.S. TRADING CORP. FILES FEDERAL SUIT AGAINST PUBLICLY TRADED PAR PHARMACEUTICAL AND ITS PARENT PHARMACEUTICAL RESOURCES
CLASS ACTION PETITION HEARING SET FOR SEPT. 16 IN DETROIT: TARGETS GENERIC PHARMACEUTICAL MAKER FOR PRODUCING FRAUDULENT, UNSAFE DRUGS
/ C O R R E C T I O N -- CLASS ACTION PETITION HEARING /
FEDERAL JUDGE GRANTS CLASS ACTION PETITION AGAINST GENERIC DRUG MAKER
Somerset Initiates Legal Action Against FDA
Consumer class actions follow suits by generic drug makers against brand-name companies.
Consumers Accuse Maker of Hormone Replacement Therapy Drug Estratest of End-Run Around FDA Regulations; Seniors Say Company Illegally Sells and...
Round #3 Against Pfizer: 10 New Personal Injury Lawsuits Filed Over Undisclosed Risks of Blockbuster Cholesterol Drug Lipitor.
Mutual Pharmaceutical Company Files Counter Suit Against Adams Respiratory Therapeutics.
False claims suit needs specifics.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters